Bergmann L - Search Results

1

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.

Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Donskov F, et al. Among authors: bergmann l. Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27. Eur J Cancer. 2020. PMID: 31887537 Free PMC article. Clinical Trial.

2

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.

3

Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.

Albiges L, Kube U, Eymard JC, Schmidinger M, Bamias A, Kelkouli N, Mraz B, Florini S, Guderian G, Cattaneo A, Bergmann L. Albiges L, et al. Among authors: bergmann l. Eur J Cancer. 2015 Nov;51(16):2368-74. doi: 10.1016/j.ejca.2015.07.030. Epub 2015 Aug 11. Eur J Cancer. 2015. PMID: 26276039

4

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H. Bergmann L, et al. Eur J Cancer. 2015 Jan;51(1):27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5. Eur J Cancer. 2015. PMID: 25459392 Clinical Trial.

5

Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.

Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS. Bergmann L, et al. Cancer. 1993 Sep 1;72(5):1733-42. doi: 10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x. Cancer. 1993. PMID: 8348502 Clinical Trial.

6

A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).

Grünwald V, Hilser T, Meiler J, Goebell PJ, Ivanyi P, Strauss A, Hartmann A, Bedke J, Bergmann L. Grünwald V, et al. Among authors: bergmann l. Oncol Res Treat. 2022;45(5):272-280. doi: 10.1159/000522043. Epub 2022 Jan 19. Oncol Res Treat. 2022. PMID: 35045416 Free article. Clinical Trial.

7

Temsirolimus for advanced renal cell carcinoma.

Bergmann L, Maute L, Guschmann M. Bergmann L, et al. Expert Rev Anticancer Ther. 2014 Jan;14(1):9-21. doi: 10.1586/14737140.2014.864562. Epub 2013 Dec 6. Expert Rev Anticancer Ther. 2014. PMID: 24313573

8

Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.

Bergmann L, Kube U, Doehn C, Steiner T, Goebell PJ, Kindler M, Herrmann E, Janssen J, Weikert S, Scheffler MT, Schmitz J, Albrecht M, Staehler M. Bergmann L, et al. BMC Cancer. 2015 Apr 18;15:303. doi: 10.1186/s12885-015-1309-7. BMC Cancer. 2015. PMID: 25925846 Free PMC article. Clinical Trial.

9

Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice.

Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE. Bergmann L, et al. Oncol Res Treat. 2014;37(3):136-41. doi: 10.1159/000360179. Epub 2014 Feb 21. Oncol Res Treat. 2014. PMID: 24685918 Free article.

10

Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.

Bergmann L, Karakas T, Knuth A, Lautenschläger G, Mitrou PS, Hoelzer D. Bergmann L, et al. Eur J Cancer. 1995 Dec;31A(13-14):2164-8. doi: 10.1016/0959-8049(95)00195-6. Eur J Cancer. 1995. PMID: 8652236 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

492 results

Search Page